Evaluation of an Ayurvedic polyherbal formulation (Sindhuvaradi agada) in Doxorubicin induced Cardiotoxicity- in wistar rats

Background: Presently cancer is second major cause of death in India. Doxorubicin, an anthracycline is frequently used to treat various human malignancies but at same time its use is warranted with irreversible cardiomyopathy. Ayurveda, ancient science of Medicine has advocated various herbal drugs...

Full description

Saved in:
Bibliographic Details
Main Authors: Shrutika Subhash Karoshi (Author), Kolume Dugeppa Govindappa (Author), Kalanghot Padmanabhan Skandhan (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2018-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_05d33fc3d0aa4d0ab2e9b8738f1acb24
042 |a dc 
100 1 0 |a Shrutika Subhash Karoshi  |e author 
700 1 0 |a Kolume Dugeppa Govindappa  |e author 
700 1 0 |a Kalanghot Padmanabhan Skandhan  |e author 
245 0 0 |a Evaluation of an Ayurvedic polyherbal formulation (Sindhuvaradi agada) in Doxorubicin induced Cardiotoxicity- in wistar rats 
260 |b Wolters Kluwer Medknow Publications,   |c 2018-01-01T00:00:00Z. 
500 |a 2772-6010 
500 |a 2772-6029 
520 |a Background: Presently cancer is second major cause of death in India. Doxorubicin, an anthracycline is frequently used to treat various human malignancies but at same time its use is warranted with irreversible cardiomyopathy. Ayurveda, ancient science of Medicine has advocated various herbal drugs for toxicological cases which include protection of Hrudaya (cardio-protective) and Sindhuvaradhi agada is one of them indicated for cobra envenomation. Objective: Study was aimed to evaluate Sindhuvaradi agada in Doxorubicin induced cardio-toxicity in Wistar rats. Methodology: Group I served as control. Cardio-toxicity was induced by Doxorubicin administration (15 mg/kg body weight for 2 weeks) in Group II. Group III was pretreated with aqueous solution of Sindhuvaradi agada (216 mg/kg body weight) for 2 weeks followed by Doxorubicin for next 2 weeks. In Group IV cardio-toxicity was produced by Doxorubicin administration for 2 weeks followed by administration of Sindhuvaradi agada in next 2 weeks. General mortality, histopathology of heart and biomarker enzymes (CPK-MB, SGOT, SGPT and Lipid Profile)was evaluated. Results: Pretreatment with Sindhuvaradi agada significantly (p<0.05) controlled myocardial damage as reflected in biomarker enzymes [CPK-MB (241.3 ± 5.25), SGOT (225.8 ± 6.63)] and also minimized the cardio myocyte damage when compared to Doxorubicin treated group [CPK-MB (258.8 ±18.33),SGOT(534 ± 102.8)]. 
546 |a EN 
690 |a cardio-toxicity 
690 |a sindhuvaradi agada 
690 |a nirgundi 
690 |a doxorubicin 
690 |a cancer. 
690 |a Other systems of medicine 
690 |a RZ201-999 
655 7 |a article  |2 local 
786 0 |n Indian Journal of Ayurveda and Integrative Medicine KLEU, Vol 1, Iss 1, Pp 39-42 (2018) 
787 0 |n http://www.ijaim.in/article.asp?issn=2772-6010;year=2018;volume=1;issue=1;spage=39;epage=42;aulast=Karoshi 
787 0 |n https://doaj.org/toc/2772-6010 
787 0 |n https://doaj.org/toc/2772-6029 
856 4 1 |u https://doaj.org/article/05d33fc3d0aa4d0ab2e9b8738f1acb24  |z Connect to this object online.